Researchers showed that the company's chips can be used to rapidly isolate exosomes from plasma or whole blood samples, allowing testing of cancer diagnostic markers.
The firm will advance an exosome isolation technology that it says allows for the capture of exosomes more efficiently and sensitively than existing platforms.
The funds will support a variety of business activities including diagnostic test development and the advance of new methods for tissue-specific exosome isolation.
The moves underscore a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for next-generation tests and therapies.
The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.
With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.
Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
Researchers showed it could differentiate pancreatic cancer cases from controls with high sensitivity, and believe it could work similarly for other cancers or in infectious disease.
The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.